Pennsylvania is currently home to 3305 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis
NCT04921345
Recruiting
The purpose of this study is to assess the pharmacokinetics (PK), efficacy, and safety of nemolizumab in pediatric participants with moderate-to-severe atopic dermatitis (AD).
Gender:
ALL
Ages:
Between 2 years and 12 years
Trial Updated:
04/05/2023
Locations: Galderma Investigational Site #8255, Philadelphia, Pennsylvania
Conditions: Moderate-to-Severe Atopic Dermatitis
Register for Updates
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
NCT02205762
Recruiting
The LCH-IV is an international, multicenter, prospective clinical study for pediatric Langerhans Cell Histiocytosis LCH (age \< 18 years).
Gender:
ALL
Ages:
18 years and below
Trial Updated:
03/21/2023
Locations: UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Langerhans Cell Histiocytosis
Register for Updates
Burst-Type Deep Brain Stimulation of the Subthalamic Nucleus in Parkinson's Disease
NCT05753449
Recruiting
This is a study to evaluate Deep brain stimulation (DBS) burst-type electrical stimulation programming verses standard DBS programming. Burst-type DBS is defined as a novel stimulation protocol in which intermittent bursts of traditional high-frequency rectangular wave stimulation are delivered. Burst type DBS may improve the efficacy and durability of DBS pulse generator.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
03/01/2023
Locations: AHN Allegheny General Hospital, Pittsburgh, Pennsylvania
Conditions: Parkinson Disease, Deep Brain Stimulation
Register for Updates
Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma
NCT03787602
Recruiting
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with Merkel Cell Carcinoma (MCC) who have failed treatment with at least one anti-PD-1 or anti-PD-L1 immunotherapy or in combination with avelumab in MCC patients who are anti-PD-1 or anti-PD-L1 treatment naïve. Inhibition of MDM2 is a novel mechanism of action in MCC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2023
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Conditions: Merkel Cell Carcinoma
Register for Updates
Sharing Digital Self-Monitoring Data With Others to Enhance Long-Term Weight Loss
NCT05180448
Recruiting
Adults attempting weight loss through lifestyle modification (LM) typically find maintenance of behavior change difficult. Outcomes might be improved if participants are provided with sustained sources of accountability and support and ongoing opportunities to reflect with others on goal progress. This study proposes that sharing digital data with other parties has the potential to improve long-term weight loss. The proposed study will enroll adults ("index participants") (N = 320) with overweig... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
02/23/2023
Locations: Drexel University, Philadelphia, Pennsylvania
Conditions: Overweight, Obesity
Register for Updates
5-aminolevulinic Acid In Advanced Malignancies
NCT04443686
Recruiting
This is a phase 1, open label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study to determine the maximum tolerated doses (MTD) or recommended phase 2 doses (RP2D) of both ALA and RT. Once the MTDs are identified, the cohort providing the highest dose intensity at or below the MTD (if supported by emerging PK and biomarker data) will be selected for an expansion phase for the purpose of refining the safety assessment and assessing preliminary efficacy. The initial dose escalati... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/20/2023
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Conditions: Advanced Solid Tumor
Register for Updates
CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer
NCT05210283
Recruiting
The CORRECT - MRD II study will prospectively enroll patients who have undergone complete surgical resection for stage II or III colorectal cancer. Patients will be followed for a minimum of 3 years and up to 5 years for recurrence.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/01/2023
Locations: UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
Conditions: Colorectal Cancer
Register for Updates
Sustaining Remission From PTSD Using Tuned Vibroacoustic Stimulation (TVS) Following MDMA-Assisted Psychotherapy
NCT05274230
Recruiting
The purpose of this research is to examine a wearable device called Apollo that emits gentle vibrations found to benefit mood, energy, and focus. We want to understand how it affects outcomes related to MDMA-assisted psychotherapy for PTSD including depression, anxiety and emotion regulation. This study will test whether regular use of the Apollo wearable improves rates of sustained symptom remission in PTSD following MDMA-assisted psychotherapy over the course of two years
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/31/2023
Locations: Apollo Neuroscience, Inc., Pittsburgh, Pennsylvania
Conditions: Stress Disorders, Post-Traumatic
Register for Updates
Rett Syndrome Registry
NCT05432349
Recruiting
The Rett Syndrome Registry is a longitudinal observational study of individuals with MECP2 mutations and a diagnosis of Rett syndrome. Designed together with the IRSF Rett Syndrome Center of Excellence Network medical directors, this study collects data on the signs and symptoms of Rett syndrome as reported by the Rett syndrome experts and by the caregivers of individuals with Rett syndrome. This study will be used to develop consensus based guidelines for the care of your loved ones with Rett s... Read More
Gender:
ALL
Ages:
Between 0 years and 99 years
Trial Updated:
01/09/2023
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Rett Syndrome, Rett Syndrome, Atypical, Genetic Disease, Genetic Diseases, X-Linked, Intellectual Disability, Neurobehavioral Manifestations, Neurologic Manifestations, Neurologic Disorder, Neurodevelopmental Disorders, Nervous System Diseases
Register for Updates
Proton and Photon Consortium Registry (PPCR): A Multi Center Registry of Pediatric Patients Treated With Radiation Therapy
NCT01696721
Recruiting
In previous studies, Proton Beam Radiation Therapy (PBRT) has been found to show better results in treating patients with cancer, both because there is better control of where in the body the radiation is directed and because it is associated with less severe long term side effects. However, there is limited published data demonstrating these results. The goal of the Proton and Photon Consortium Registry (PPCR) is to enroll children treated with radiation in order to describe the population that... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
01/05/2023
Locations: University of Pennsylvania - Roberts Proton Therapy Center, Philadelphia, Pennsylvania
Conditions: Pediatric Patients Treated With Radiation Therapy
Register for Updates
Knee Related Subchondral Bone Lesions Treated With IOBP
NCT05314608
Recruiting
The study will be a prospective, multicenter clinical study evaluating clinical and patient reported outcome measures of subjects receiving IOBP® surgical technique using Angel cPRP and BMA processing system to treat subchondral bone pathology (SBP).
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
12/02/2022
Locations: Allegheny-Singer Research Institute, Pittsburgh, Pennsylvania
Conditions: Subchondral Cyst
Register for Updates
2-level Cervical Disc Replacement Comparing Prodisc C SK & Vivo to Mobi-C
NCT04012996
Recruiting
A multi-center, prospective, randomized, controlled comparison of the prodisc C SK and prodisc C Vivo to the control, a similar, legally marketed total disc replacement device in subjects with symptomatic cervical disc disease (SCDD).
Gender:
ALL
Ages:
Between 18 years and 69 years
Trial Updated:
10/27/2022
Locations: Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania
Conditions: Symptomatic Cervical Disc Disease
Register for Updates